RXST 44.83 Stock Price RxSight, Inc.
Range: | 28.54-66.54 | Vol Avg: | 479175 | Last Div: | 0 | Changes: | -0.22 |
Beta: | 1.19 | Cap: | 1.81B | Currency: | USD | Exchange: | NASDAQ |
Sector: | Healthcare | IPO: | Fri Jul 30 2021 | Empoloyees: | 374 |
CUSIP: | 78349D107 | CIK: | 0001111485 | ISIN: | US78349D1072 | Country: | US |
CEO: | Dr. Ronald M. Kurtz M.D. | Website: | https://www.rxsight.com |
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.